| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 35.59% | Canaccord Genuity | $20 → $12 | Maintains | Buy |
| 09/05/2023 | 103.39% | Craig-Hallum | → $18 | Initiates Coverage On | → Buy |
| 08/03/2023 | 92.09% | Piper Sandler | $15 → $17 | Maintains | Overweight |
| 07/11/2023 | 80.79% | Citigroup | $14 → $16 | Maintains | Buy |
| 05/03/2023 | 58.19% | Citigroup | $13 → $14 | Maintains | Buy |
| 05/03/2023 | 69.49% | Piper Sandler | $13 → $15 | Maintains | Overweight |
| 05/03/2023 | 58.19% | Morgan Stanley | $11 → $14 | Maintains | Equal-Weight |
| 04/03/2023 | 46.89% | Citigroup | $12 → $13 | Maintains | Buy |
| 02/27/2023 | 69.49% | Wells Fargo | $10 → $15 | Upgrades | Equal-Weight → Overweight |
| 02/24/2023 | 35.59% | Citigroup | $10 → $12 | Maintains | Buy |
| 02/23/2023 | 125.99% | Canaccord Genuity | $18 → $20 | Maintains | Buy |
| 02/23/2023 | 24.29% | Morgan Stanley | $9.5 → $11 | Maintains | Equal-Weight |
| 01/06/2023 | 7.34% | Morgan Stanley | $14 → $9.5 | Maintains | Equal-Weight |
| 01/03/2023 | -9.6% | B of A Securities | → $8 | Downgrades | Neutral → Underperform |
| 12/12/2022 | -32.2% | Wells Fargo | $13.5 → $6 | Maintains | Equal-Weight |
| 12/12/2022 | 12.99% | Citigroup | $14 → $10 | Upgrades | Neutral → Buy |
| 11/07/2022 | 58.19% | Morgan Stanley | $19 → $14 | Maintains | Equal-Weight |
| 11/04/2022 | 46.89% | Piper Sandler | $25 → $13 | Maintains | Overweight |
| 10/11/2022 | 114.69% | Morgan Stanley | $21 → $19 | Maintains | Equal-Weight |
| 08/04/2022 | 137.29% | Morgan Stanley | $19 → $21 | Maintains | Equal-Weight |
| 08/03/2022 | 182.49% | Piper Sandler | $37 → $25 | Maintains | Overweight |
| 07/18/2022 | 125.99% | Stifel | $32 → $20 | Maintains | Buy |
| 07/15/2022 | 114.69% | Morgan Stanley | $30 → $19 | Maintains | Equal-Weight |
| 07/11/2022 | 114.69% | Citigroup | $23 → $19 | Downgrades | Buy → Neutral |
| 05/17/2022 | 159.89% | Citigroup | $32 → $23 | Maintains | Buy |
| 02/25/2022 | 238.98% | Morgan Stanley | $37 → $30 | Maintains | Equal-Weight |
| 02/24/2022 | 205.08% | Wells Fargo | $55 → $27 | Maintains | Equal-Weight |
| 01/07/2022 | 318.08% | Morgan Stanley | $48 → $37 | Maintains | Equal-Weight |
| 12/08/2021 | 408.47% | Piper Sandler | → $45 | Upgrades | Neutral → Overweight |
| 11/03/2021 | 521.47% | Wells Fargo | $56 → $55 | Maintains | Equal-Weight |
| 08/04/2021 | 498.87% | Canaccord Genuity | $65 → $53 | Maintains | Buy |
| 04/01/2021 | 577.97% | Citigroup | → $60 | Initiates Coverage On | → Buy |
| 03/25/2021 | 464.97% | Piper Sandler | → $50 | Initiates Coverage On | → Neutral |
| 03/10/2021 | 713.56% | B of A Securities | → $72 | Upgrades | Neutral → Buy |
| 03/03/2021 | 634.46% | Canaccord Genuity | $49 → $65 | Maintains | Buy |
| 03/03/2021 | 498.87% | Morgan Stanley | $52 → $53 | Maintains | Equal-Weight |
| 12/15/2020 | 487.57% | Morgan Stanley | $46 → $52 | Maintains | Equal-Weight |
| 11/11/2020 | 419.77% | Morgan Stanley | $44 → $46 | Maintains | Equal-Weight |
| 10/26/2020 | 464.97% | B of A Securities | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 453.67% | Canaccord Genuity | → $49 | Initiates Coverage On | → Buy |
| 10/26/2020 | 464.97% | Stifel | → $50 | Initiates Coverage On | → Buy |
| 10/26/2020 | 397.18% | Morgan Stanley | → $44 | Initiates Coverage On | → Equal-Weight |
| 10/26/2020 | 419.77% | Wells Fargo | → $46 | Initiates Coverage On | → Equal-Weight |
What is the target price for Pulmonx (LUNG)?
The latest price target for Pulmonx (NASDAQ: LUNG) was reported by Canaccord Genuity on October 31, 2023. The analyst firm set a price target for $12.00 expecting LUNG to rise to within 12 months (a possible 35.59% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pulmonx (LUNG)?
The latest analyst rating for Pulmonx (NASDAQ: LUNG) was provided by Canaccord Genuity, and Pulmonx maintained their buy rating.
When is the next analyst rating going to be posted or updated for Pulmonx (LUNG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pulmonx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pulmonx was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
Is the Analyst Rating Pulmonx (LUNG) correct?
While ratings are subjective and will change, the latest Pulmonx (LUNG) rating was a maintained with a price target of $20.00 to $12.00. The current price Pulmonx (LUNG) is trading at is $8.85, which is out of the analyst's predicted range.